55416

Analysis of the hpv prevalence and mass vaccination

ANA LETÍCIA VIEIRA DE OLIVEIRA PINHEIRO ; BRUNO SOUZA BENEVIDES ; GABRIELA ALMEIDA BAN ; GISELE FAÇANHA DIÓGENES TEIXEIRA ; GISELE TAHIM DE SOUSA BRASIL OTHON SIDOU ; JÉSSICA BANDEIRA DE LAVÔR FARIAS ; JOSEANE MARQUES FERNANDES ; JULIANA LANDIM VIANA ; LARISSA DA SILVA NOBRE ; MARIA AMÉLIA PINHEIRO DE OLIVEIRA ; NARA MIRELLA TEIXEIRA PAIVA ; SARAH DIÓGENES ALENCAR ; THAÍS DE BRITO ROCHA
Favoritar este trabalho

Introduction: Human Papillomavirus (HPV) is a DNA virus, encapsulated, belonging to Papovaviridae family with carcinogenic character, associated to cancer of the cervix, second leading cause of cancer in women. HPV is the most common STD among both men and women, affecting mainly between 18-28 years. This disease is characterized by warty lesions, itching, burning sensation, dyspareunia, pain and bleeding. In 2015, the Brazilian government plans to vaccinate girls aged 9 to 13 years, trying to cover the age group that has not yet started their sex life. Objectives: To evaluate the magnitude of HPV in women attending a Primary Care Unit in Health, in Fortaleza-CE. Methodology: A retrospective cross-sectional study were reviewed medical records of 3438 patients referred from 1 July 2010 to 31 July 2015 at the UBS Mirian Porto Mota in Fortaleza, Ceará. Results: The prevalence was 0.23% (n = 8) HPV positive. The average age of these was 32.63 years, ranging from 19 to 48. Conclusion: The prevalence of HPV in the population studied was lower than what has been observed in the literature, whereas the variation in prevalence in different populations it is (ranging from 1.4% to 25.6%). Vaccination may be useful when considering the prevalence of 90% of HPV in women with cervical cancer and taking into account the financial expenditure of vaccination is less than the direct and indirect cost of treating this disease.